Currently, a phase I/IIa clinical trial (NeoRay, NCT03872778) is ongoing in which the safety, tolerability, pharmacokinetics, distribution, radiation dosimetry, and anti-tumor activity of [177Lu]Lu-NeoB are investigated in patients with tumors known to overexpress GRPR. Here, GRPR is linked to neoplasm.